


PRODUCT INFORMATION



Bafetinib

Item No. 19169

CAS Registry No.: 859212-16-1
Formal Name: N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-benzamide



Synonyms: INNO-406, NS-187
MF: C₃₀H₃₁F₃N₈O
FW: 576.6
Purity: ≥95%
UV/Vis.: λ_{max}: 232 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Bafetinib is supplied as a crystalline solid. A stock solution may be made by dissolving the bafetinib in the solvent of choice. Bafetinib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of bafetinib in ethanol and DMF is approximately 25 mg/ml and approximately 15 mg/ml in DMSO.

Bafetinib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, bafetinib should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Bafetinib has a solubility of approximately 0.25 mg/ml in a 1:3 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Bcr-Abl, a fusion protein with deregulated tyrosine kinase activity, is highly expressed in chronic myelogenous leukemia (CML). Bafetinib is a rationally developed tyrosine kinase inhibitor based on the chemical structure of imatinib (Item No. 13139), with modifications added to improve binding and potency against Bcr-Abl kinase (IC₅₀ = 5.8 nM).¹ It is 25- to 55-fold more potent than imatinib *in vitro* and ≥10-fold more potent *in vivo*.¹ Bafetinib inhibits 12 out of the 13 most frequent imatinib-resistant Bcr-Abl point mutations, but not the T315I mutation and also targets the Src family kinase Lyn (IC₅₀ = 19 nM), which has been associated with resistance to imatinib in CML.¹

Reference

1. Kimura, S., Naito, H., Segawa, H., *et al.* NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. *Blood* **106**(12), 3948-3954 (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM